MedTrace Logo

Risk Assessment of Febrile Neutropenia and Grade 3-4 Neutropenia in Patients With Non-hematological Cancer Treated With Conventional Chemotherapy

NCT01799421 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 420

Last updated 2016-11-21

No results posted yet for this study

Summary

The purpose of this study is to identify prognostic factors and to develop predictive models of risk of febrile neutropenia and neutropenia grade 3/4 in patients with solid tumors receiving chemotherapy with schemas that have an inherent risk of febrile neutropenia of 10-20%.

Conditions

  • Non-hematologic Cancer

Sponsors & Collaborators

  • Asociación para el Fomento de la Investigación y el Desarrollo Integral de la Oncología

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2014-12-31
Completion
2015-12-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01799421 on ClinicalTrials.gov